MX2015013414A - N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. - Google Patents

N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.

Info

Publication number
MX2015013414A
MX2015013414A MX2015013414A MX2015013414A MX2015013414A MX 2015013414 A MX2015013414 A MX 2015013414A MX 2015013414 A MX2015013414 A MX 2015013414A MX 2015013414 A MX2015013414 A MX 2015013414A MX 2015013414 A MX2015013414 A MX 2015013414A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
janus kinase
pyridones
pyrazolo
heterocyclyl
Prior art date
Application number
MX2015013414A
Other languages
English (en)
Spanish (es)
Inventor
Christopher F Thompson
Jianmin Fu
Hongbo Zeng
Mark E Scott
Jason Brubaker
Joshua T Close
Danielle Falcone
Ravi Kurukulasuriya
Peter Fuller
David Guerin
Jason David Katz
Qinglin Pu
Yunfeng Bai
Norman Kong
Yumei Liu
Zhixiang Zheng
Christopher Dinsmore
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2015013414A publication Critical patent/MX2015013414A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015013414A 2013-03-19 2014-03-19 N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. MX2015013414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361803226P 2013-03-19 2013-03-19
PCT/CN2014/000298 WO2014146492A1 (en) 2013-03-19 2014-03-19 N-(2-cyano heterocyclyl)pyrazolo pyridones as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015013414A true MX2015013414A (es) 2016-02-26

Family

ID=51579321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013414A MX2015013414A (es) 2013-03-19 2014-03-19 N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.

Country Status (11)

Country Link
US (1) US9957265B2 (enExample)
EP (1) EP2976338B1 (enExample)
JP (1) JP6322275B2 (enExample)
KR (1) KR20150130311A (enExample)
CN (1) CN105189497B (enExample)
AU (1) AU2014234908B2 (enExample)
BR (1) BR112015023878A2 (enExample)
CA (1) CA2901766A1 (enExample)
MX (1) MX2015013414A (enExample)
RU (1) RU2669922C2 (enExample)
WO (1) WO2014146492A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014146246A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
WO2016061751A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
WO2018111663A1 (en) * 2016-12-14 2018-06-21 Merck Sharp & Dohme Corp. Aminopyrazoles as janus kinase inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111499592B (zh) * 2020-03-14 2023-06-23 江苏省农用激素工程技术研究中心有限公司 5-氨甲基糖精的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2759227B2 (ja) 1990-09-28 1998-05-28 大鵬薬品工業株式会社 ピラゾロピリジン誘導体
CN1636005A (zh) 1999-06-03 2005-07-06 克诺尔股份有限公司 苯并噻嗪酮和苯并噁嗪酮化合物
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
JP4139185B2 (ja) 2002-10-17 2008-08-27 京セラ株式会社 配線基板の製造方法
NZ601687A (en) * 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
JP5287253B2 (ja) 2007-01-12 2013-09-11 アステラス製薬株式会社 縮合ピリジン化合物
US9346809B2 (en) 2009-07-08 2016-05-24 Leo Pharma A/S Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
ES2633793T3 (es) * 2011-09-22 2017-09-25 Merck Sharp & Dohme Corp. Pirazol carboxamidas como inhibidores de quinasa Janus
EP2857400A4 (en) 2012-06-01 2015-12-09 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
WO2014146246A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors

Also Published As

Publication number Publication date
US9957265B2 (en) 2018-05-01
JP2016514710A (ja) 2016-05-23
EP2976338A4 (en) 2016-08-31
AU2014234908A1 (en) 2015-08-13
RU2015144483A (ru) 2017-04-25
RU2669922C2 (ru) 2018-10-17
US20160272633A1 (en) 2016-09-22
BR112015023878A2 (pt) 2017-07-18
CN105189497A (zh) 2015-12-23
EP2976338A1 (en) 2016-01-27
CN105189497B (zh) 2019-05-03
WO2014146492A1 (en) 2014-09-25
CA2901766A1 (en) 2014-09-25
KR20150130311A (ko) 2015-11-23
EP2976338B1 (en) 2018-01-03
AU2014234908B2 (en) 2017-08-17
JP6322275B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
GB201209587D0 (en) Therapeutic compounds
MX2015013418A (es) Cicloalquil nitrilo pirazolo piridonas como inhibidores de janus quinasa.
TW201613864A (en) Novel compounds
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
PH12015501038A1 (en) Inhibitors of iap
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX372740B (es) Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).